Experts discuss quadruplet therapy, MRD, and evolving transplant decisions in newly diagnosed multiple myeloma. Dr. Amir Fathi discusses oral regimens and future AML therapy trends in this Editor’s Special of The HemOnc Pulse. Can tech bridge the cancer care gap? Dr. Banerjee and Dr. Longmire explore solutions for drug accessibility. Experts explore CAR T therapy challenges and the future of lymphoma care beyond CD19-targeted treatments. Experts discuss early detection in myeloid malignancies, from current challenges to future innovations. At The HemOnc Pulse Live!, experts debate key controversies in MDS care, from frontline therapy to emerging treatments. Gurbakhash Kaur, MD joins the host of The HemOnc Pulse Live! for a comprehensive discussion about the RedirecT-1 trial. Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference. Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting. Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology. Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting. Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting. Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS. Rami Komrokji, MD, describes incorporation of molecular data, tailoring treatment by disease risk, and new therapies in MDS. Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more. Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies. HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients. "Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode. It's many different diseases, and it falls across many different specialties, according to the Dr. Goodman. Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.